| Trial of Pegasys® in Patients With Chronic Hepatitis C (NCT00245414) | Chugai Pharmaceutical | 2005-10-01 |
| Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin (NCT00196664) | French National Agency for Research on AIDS and Viral Hepatitis | 2005-10-01 |
| Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED) (NCT00160251) | Merck Sharp & Dohme LLC | 2005-09-01 |
| 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV (NCT00225537) | MTmedical Institute of Health | 2005-09-01 |
| Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin (NCT00230854) | OPKO Health, Inc. | 2005-08-01 |
| A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C (NCT00118768) | Merck Sharp & Dohme LLC | 2005-08-01 |
| Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial (NCT00211692) | Minneapolis Veterans Affairs Medical Center | 2005-07-01 |
| Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication (NCT00296972) | University Health Network, Toronto | 2005-07-01 |
| Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease (NCT00172809) | National Taiwan University Hospital | 2005-07-01 |
| Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) (NCT00704964) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment (NCT00844272) | Universitätsklinikum Hamburg-Eppendorf | 2005-05-01 |
| Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. (NCT00502086) | Catalysis SL | 2005-05-01 |
| A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients (NCT00629967) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2005-04-01 |
| Study of Nitazoxanide in the Treatment of Chronic Hepatitis C (NCT00418639) | Romark Laboratories L.C. | 2005-02-01 |
| Hepatitis C Treatment in Underserved Populations (NCT01717560) | Brian Edlin | 2005-02-01 |
| Pioglitazone in Hepatitis C (NCT00189163) | University of Michigan | 2005-01-01 |
| Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy (NCT00120861) | Merck Sharp & Dohme LLC | 2005-01-01 |
| Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin (NCT00635310) | National Taiwan University Hospital | 2005-01-01 |
| PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C (NCT00100659) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2004-12-01 |
| Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin. (NCT01178996) | sigma-tau i.f.r. S.p.A. | 2004-12-01 |
| Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 (NCT00575224) | Pacific Health Foundation | 2004-10-01 |
| Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C (NCT00120835) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (NCT00093093) | Bausch Health Americas, Inc. | 2004-06-01 |
| Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (NCT00086541) | Bausch Health Americas, Inc. | 2004-06-01 |
| CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders) (NCT00084279) | InterMune | 2004-04-01 |
| Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy (NCT01120795) | Melbourne Health | 2004-02-01 |
| The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C (NCT01464008) | Beijing Ditan Hospital | 2004-01-01 |
| Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive (NCT00230958) | Bausch Health Americas, Inc. | 2003-12-01 |
| Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C (NCT00209755) | Hopital A Michallon | 2003-10-01 |
| Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection (NCT00352235) | Foundation for Liver Research | 2003-08-01 |
| Hepatitis C Treatment of Inmates (NCT00209898) | Haukeland University Hospital | 2003-08-01 |
| Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C (NCT01596517) | Asan Medical Center | 2003-06-01 |
| Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients (NCT00196586) | French National Agency for Research on AIDS and Viral Hepatitis | 2003-04-01 |
| Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C (NCT00298714) | Hospital Clinic of Barcelona | 2003-03-01 |
| Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C (NCT00227435) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine (NCT00602784) | Valneva Austria GmbH | 2002-11-01 |
| Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) (NCT00049842) | Merck Sharp & Dohme LLC | 2002-10-01 |
| Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211) (NCT00158496) | French National Agency for Research on AIDS and Viral Hepatitis | 2002-08-01 |
| Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C (NCT00200343) | Tanabe Pharma Corporation | 2002-07-01 |
| Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) (NCT00048724) | Merck Sharp & Dohme LLC | 2002-06-01 |
| A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C (NCT00144469) | Chugai Pharmaceutical | 2002-05-01 |
| Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy (NCT00351871) | Louisiana State University Health Sciences Center in New Orleans | 2002-04-01 |
| Gamma Interferon Therapy for Chronic Hepatitis C (NCT00028275) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2001-12-01 |
| Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions (NCT00959933) | Sandoz | 2001-04-01 |
| Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions (NCT00960479) | Sandoz | 2001-01-01 |
| Natural History of Hepatitis C in Patients With Normal Liver Tests (NCT00187473) | University of California, San Francisco | 2000-06-01 |
| Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment (NCT00006164) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2000-06-01 |
| Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients (NCT00146016) | UMC Utrecht | 2000-02-01 |
| Long-Term Therapy With Ribavirin for Chronic Hepatitis C (NCT00001854) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1999-02-12 |
| Combination Drug Therapy for Patients With Hepatitis C (NCT00001729) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1997-10-01 |
| EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C (NCT02097966) | Bristol-Myers Squibb | |
| Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV (NCT01113814) | Johann Wolfgang Goethe University Hospital | |
| Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment (NCT00909129) | Karolinska Institutet | |
| A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C (NCT02161939) | Bristol-Myers Squibb | |
| Vitamin D Treatment in Patients With Chronic Hepatitis C (NCT00804752) | Hillel Yaffe Medical Center | |